Terms: = Leukemia AND GOPC, FIG, 57120, ENSG00000047932, GOPC1, Q9HD26, CAL, dJ94G16_2 PIST AND Treatment
57 results:
1. 4-Carbomethoxyl-10-Epigyrosanoldie E Extracted from Cultured Soft Coral
She YY; Lin JJ; Su JH; Chang TS; Wu YJ
Oxid Med Cell Longev; 2022; 2022():3017807. PubMed ID: 36275891
[TBL] [Abstract] [Full Text] [Related]
2. Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells.
Nova-Camacho LM; Val-Carreres Castellote A; Riego Repullo V
Rev Esp Enferm Dig; 2022 Aug; 114(8):510-511. PubMed ID: 35297262
[TBL] [Abstract] [Full Text] [Related]
3. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
[TBL] [Abstract] [Full Text] [Related]
4. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.
Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y
Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636
[TBL] [Abstract] [Full Text] [Related]
5. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
Mehrpouri M; Momeny M; Bashash D
J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract] [Full Text] [Related]
7. Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.
Janikashvili N; Gérard C; Thébault M; Brazdova A; Boibessot C; Cladière C; Ciudad M; Greigert H; Ouandji S; Ghesquière T; Samson M; Audia S; Saas P; Bonnotte B
Oncoimmunology; 2021 Feb; 10(1):1880046. PubMed ID: 33659098
[TBL] [Abstract] [Full Text] [Related]
8. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
[TBL] [Abstract] [Full Text] [Related]
9. Does the platelet‑to‑lymphocyte ratio have a prognostic effect in patients with myelodysplastic syndrome?
Yikilmaz AS; Akinci S; Bakanay SM; Dilek I
Bratisl Lek Listy; 2020; 121(6):422-427. PubMed ID: 32484706
[TBL] [Abstract] [Full Text] [Related]
10. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Kienle DL; Stilgenbauer S
Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia.
Yurt M; Ayyildiz O; Karakus A; Nursal AF; Isi H
Bratisl Lek Listy; 2020; 121(2):159-163. PubMed ID: 32115971
[TBL] [Abstract] [Full Text] [Related]
12. New principles of cancer therapy give new hope for oncological patients.
Bernadic M; Duchon R; Aziri R; Mladosievicova B
Bratisl Lek Listy; 2019; 120(1):15-18. PubMed ID: 30685987
[TBL] [Abstract] [Full Text] [Related]
13. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract] [Full Text] [Related]
14. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
[TBL] [Abstract] [Full Text] [Related]
16. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
[TBL] [Abstract] [Full Text] [Related]
17. PI3K-δ inhibition using cal-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
[TBL] [Abstract] [Full Text] [Related]
18. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract] [Full Text] [Related]
19. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract] [Full Text] [Related]
20. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
[TBL] [Abstract] [Full Text] [Related]
[Next]
